About Ios Bio

COVID-19 is the perfect example of a novel virus with the ability to rapidly cause a pandemic. In the case of a highly infectious novel virus, the swift development of a vaccine is not enough. An effective vaccine needs to deliver mucosal and systemic immunity combined with how quickly an entire population can be vaccinated.

Using OraPro technology, iosbio OraPro-COVID-19 can be developed within a matter of weeks. The viral vector can be developed within days and a capsule ready for animal testing can be ready within weeks. These stages are now complete, with clinical trials due to begin, pending securing funding. Because OraPro-COVID-19 is delivered in thermally stable capsules, it can be self-administered by patients without the need for needles and healthcare professionals. The delivery mechanism eliminates the risk of potentially infected people queuing for injections, removes the need for cold-chain delivery and enables the world’s most rapid deployment of vaccines.

Journey to date

  • 2005: First Investor
  • 2009: Angel/HNW Investment round £3.3m
  • 2010: DTRA: anthrax vaccine $3.4m
  • 2013: Innovate UK: VZV thermostability
  • 2015: Development of internal pipeline
  • 2015: GSK: Collaboration, Option and Licence Agreement
  • 2015: Zoetis, animal health collaboration
  • 2016: SBRI: award for Oral Zika vaccine
  • 2018: SBRI: £2m award Oral Zika vaccine
  • 2018: Oncolys BioPharma, Inc.: License Agreement
  • 2019: OraPro-Zika cGMP campaign
  • 2020: Working on OraPro-COVID-19, emergency response

Latest News

  • 2021-02-12

    British Vaccine Deployment Minister says COVID-19 vaccine may soon be available in pill form

  • 2021-01-13

    IoSBio - ImmunityBio partnership is now public

  • 2021-01-04

    IoSBio - ImmunityBio partnership update

  • 2020-12-16

    IoSBIO partner ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate new study results

  • See more news

Key People

WAYNE CHANNON | Chairman

Wayne Channon is a successful entrepreneur with experience of managing high growth companies from start-up to exit. He has run companies in both Europe and the US. Wayne currently also chairs Cells4Life, the UK leader in the umbilical cord blood stem cell storage segment. Amongst his companies, he founded Ilion Group Plc which grew to be Europe's second largest networking distributions group with revenues of €500 million, operating in nine countries. Ilion was subsequently floated on the Official List of the London Stock Exchange. Wayne graduated from Imperial College with first class honours in mathematical physics.

JEFF DREW | CHIEF SCIENTIFIC OFFICER

Jeff Drew is the founder of Stabilitech and the developer of the company's proprietary technology. Jeff holds a degree in Microbiology and Virology from Manchester University, and a PhD in Molecular Virology from Reading University Institute of Animal Health at Pirbright, UK. Jeff has 18 years' experience in microbiological, cancer, gene therapy and genetic research. His research has been conducted within various research institutes and departments in the UK including the Exotic Virus Research Laboratories at the Institute of Animal Health, University of Oxford, University of London, the Marie Curie Research Institute and the Chester Beatty Laboratories at the Institute of Cancer Research. He is the co-founder and a non- executive director of Cells4Life, a leading UK umbilical cord blood stem cell storage company.

ELLIOT BLAND | BUSINESS DEVELOPMENT DIRECTOR

Elliot Bland is responsible for leading commercial activities on Stabilitech's development pipeline and identifying new targets for Stabilitech's novel oral vaccine platform. Formerly at Queen Mary Innovation Ltd, Elliot managed the commercialisation of life-science projects from Queen Mary University of London. Partnering with industry, he enabled the development and commercialisation of cutting edge science, generating revenues for the university and its inventors. He also produced non-clinical regulatory packages, preclinical toxicity plans and conducted scientific advice meetings with the MHRA. He now holds an honorary fellowship position at the university. Four years prior, Elliot was responsible for global business development at SLA Pharma Ltd, out-licensing a Phase III gastrointestinal treatment to a pan-European company. Previous to this, Elliot conducted innovation management & commercialisation for NHS trusts across London. Earlier in his career he held positions in a DNA diagnostic company and an AstraZeneca-SME partnership.

Dr Peter Cozens | Non-Exec Director

Dr Peter Cozens has worked for more than 30 years in the pharmaceutical industry, with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry. In 1991 he joined Medeva PLC where he became Executive Vice President, Business Development and Intellectual Property, responsible for the building of Medeva's development pipeline, managing its patents and trademark function and overseeing multinational patent litigation. Prior to Medeva he worked as a research scientist for Ciba-Geigy (now Novartis) and in R&D and business development at Wellcome (now GSK). He is currently a Partner at the consulting firm, ProPharma Partners Ltd., a member and former Chairman of the Intellectual Property Advisory Committee of the UK BioIndustry Association, and non-executive chairman of Zysis Ltd

Nigel Brooksby | Non-Exec Director

Nigel Brooksby is Chairman of the UK Life Sciences Board and Board Member of the Cogent Skills Sector Council (SSC). Previously he held senior global appointments at Wellcome (now GSK), Pfizer and Sanofi. Nigel is a past President and Lifetime Member of the Association of the British Pharmaceutical industry (ABPI). He is a past Member of the CBI's Presidential Committee and is the current Chairman of the Pharmaceutical Directors Club (PDC), a Fellow of the Royal Society of Medicine, a Fellow of the Royal Society of Arts and a Friend of the Royal College of Physicians. He is a Member of the UK Government's Industrial Advisory Board which advises the Secretary of State for Business and his Ministers on applications for investment. He holds several academic, charity and life sciences Chairmanships and Board positions, which include the Clinical Trial Unit at Imperial College London and advising the Wellcome Trust.

James Hudleston | Non-Exec Director

James Hudleston is an entrepreneur, corporate financier and highly successful investor in technology, biotechnology and the resource sector. He specialises in assisting management in the development, growth and exit of private and public companies. James is a keystone investor in Stabilitech and is its largest shareholder. He also founded Hurricane Energy, a publicly quoted oil exploration company, in 2004. Born and educated in Zimbabwe, James is a St Radegund Fellow of Jesus College, Cambridge.

Myra Waiman | Non-Exec Director

Myra Waiman is a biochemist and has worked in hospitals for a number of years before establishing Romney Consultants as a strategy and business consultancy. She has wide experience in medical device groups as well as biotech and other technical start-ups, helping them fundraise and with business development. She is director of Westgate Hall Plc, non-executive director for various companies and is a trustee of Heart Cell Foundation, Weizmann Council UK and Prism The Gift fund.

Files and Documents